Position in EXEL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$883,534
+$246,246 QoQ
Shares Held
20,600
+41.7% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Equitable Holdings, Inc. holds $7,394,893 across 13 Biotechnology names. EXEL ranks #4 (11.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LGND |
Ligand Pharmaceuticals Inc
|
9,853 | $1,967,151 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
3,464 | $1,546,814 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,829 | $1,413,158 | |
| 4 | EXEL |
Exelixis, Inc.
This page
|
20,600 | $883,534 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
21,135 | $687,732 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
12,291 | $584,682 | |
| 7 | IBRX |
ImmunityBio, Inc.
|
15,500 | $118,885 | |
| 8 | DRTS |
Alpha Tau Medical Ltd.
|
10,000 | $70,700 |
All Filings in EXEL
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $883,534 | 20,600 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $637,288 | 14,540 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $505,305 | 12,235 | Shares | Defined | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||